Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carminia M Della Corte

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cancer|January 9, 2019
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint eraCarminia M Della Corte, Carl M Gay, Lauren A Byers
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung CancerKavya Ramkumar, Azusa Tanimoto, Carminia M Della Corte, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2019
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLCTriparna Sen, Carminia M Della Corte, Snezana Milutinovic, et al.
Molecular Cancer Research : MCR|November 11, 2020
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR InhibitorsKavya Ramkumar, C Allison Stewart, Kasey R Cargill, et al.
Cancer Discovery|February 20, 2019
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung CancerTriparna Sen, B Leticia Rodriguez, Limo Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2020
STING Pathway Expression Identifies NSCLC With an Immune-Responsive PhenotypeCarminia M Della Corte, Triparna Sen, Carl M Gay, et al.
Cancer Cell|January 22, 2021
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M Gay, C Allison Stewart, Elizabeth M Park, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cancer|January 9, 2019
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint eraCarminia M Della Corte, Carl M Gay, Lauren A Byers
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung CancerKavya Ramkumar, Azusa Tanimoto, Carminia M Della Corte, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2019
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLCTriparna Sen, Carminia M Della Corte, Snezana Milutinovic, et al.
Molecular Cancer Research : MCR|November 11, 2020
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR InhibitorsKavya Ramkumar, C Allison Stewart, Kasey R Cargill, et al.
Cancer Discovery|February 20, 2019
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung CancerTriparna Sen, B Leticia Rodriguez, Limo Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2020
STING Pathway Expression Identifies NSCLC With an Immune-Responsive PhenotypeCarminia M Della Corte, Triparna Sen, Carl M Gay, et al.
Cancer Cell|January 22, 2021
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M Gay, C Allison Stewart, Elizabeth M Park, et al.
Pageof 1